Pharmaceutical Executive, Apr 1, 2014 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Apr 1, 2014
Features
Mission Critical: Assessing Pharma's Drivers of Change
By William Looney
Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Regional Trends in Bioinnovation Investment
California's Bay Area and the Boston/Cambridge nexus continue to dominate bioinnovation in the US. Pharm Exec looks at the factors contributing to the strategic dominance of these regions.
HBA's Women of the Year 2014
By Joanna Breitstein
The Healthcare Businesswomen's Association honored three female leaders this year. We take an in-depth look at each winner's background and career—and what factors helped push them to the top of their game.
Feature
Fixing Wikipedia
By Peter Houston
Will Pharma join a growing effort to make the world's leading online health information resource more relevant to providers and safer for patients? Peter Houston reports.
Column
"Market-Based" Price Controls In India?
Three strategic implications for pharma pricing strategies in India.
Sickle Cell Disease In Three Acts
By Ben Comer
Ben Comer reports on how new pipeline therapies, public research investments, and a renewed sociopolitical focus are working toward a happier outcome for sickle cell disease patients.
Whatever Happened To Faster Reimbursement For Generics In Europe?
By Reflector
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Obama Policies Reshape Pharma Marketing
By Jill Wechsler
Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.
From the Editor
Dividing Lines
By William Looney
Three examples from Pharm Exec's coverage this month show that, in our industry, there are always two sides—at least—to every question.

ADVERTISEMENT

Click here